Question explored with the scientific record
Does long-term statin use cause peripheral neuropathy?
The short version: the best evidence here says statins do not clearly cause peripheral neuropathy, but the studies are observational and the signal is not zero.
The strongest record is a 2021 systematic review and meta-analysis of observational studies. In non-diabetic people, statin users had a pooled odds ratio of 1.24 for polyneuropathy, with a confidence interval that crossed 1, so not statistically significant, but the heterogeneity was high at 74% [3]. In diabetic people the pooled odds ratio was 0.82, also not significant, with heterogeneity of 80% [3]. A separate 2021 meta-analysis reached the same overall conclusion, no significant association, again with substantial heterogeneity [1]. A 2006 safety task force called peripheral neuropathy "very rare, with conflicting evidence" [2].
| Analysis | Pooled odds ratio | Significant? |
|---|---|---|
| Non-diabetic, all studies | 1.24 | No |
| Non-diabetic, excluding Gaist | 1.07 | No |
| Non-diabetic, cohort excluded | 1.21 | No |
| Diabetic | 0.82 | No |
These are observational studies, not randomized trials. They cannot prove cause, and the wide swings when single studies are removed show how fragile the pooled estimate is [3]. The 1.24 point estimate in non-diabetics leans toward a small increased risk, not away from it. The mechanism is plausible: statins impair mitochondrial function in muscle and nerve tissue [4][5], and mitochondrial dysfunction is a documented pathway to nerve injury. That is mechanism, not proof of a neuropathy rate.
My call: for most long-term statin users the evidence does not show a clear neuropathy risk, but it does not rule out a small one, and the studies are too heterogeneous to be confident. Confidence: low to moderate.
Sources used 5
-
The association between statins exposure and peripheral neuropathy risk: A meta‐analysis
A systematic review and meta-analysis of observational studies assessing whether statin exposure influences the risk of peripheral neuropathy, finding no statistically significant association overall though with substantial heterogeneity among studies.
DOI: 10.1111/jcpt.13393 -
Final Conclusions and Recommendations of the National Lipid Association Statin Safety Assessment Task Force
This article summarizes the final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force regarding the safety of statin therapy based on extensive evidence and research.
DOI: 10.1016/j.amjcard.2006.02.030 -
Statins and the risk of polyneuropathy: A systematic review and two meta‐analyses
This systematic review and meta-analyses found no significant association between statin use and polyneuropathy risk in non-diabetic (pooled OR 1.24, 95% CI 0.88-1.76) or diabetic (pooled OR 0.82, 95% CI 0.56-1.21) populations.
DOI: 10.1002/mus.27447 -
Transcriptional deficits in oxidative phosphorylation with statin myopathy
Pre-existing energy-production deficiencies in skeletal muscle, evidenced by reduced oxidative phosphorylation gene expression and mitochondrial ribosomal protein transcripts in statin myopathy patients, contribute to statin-associated myopathy, particularly under eccentric exer…
DOI: 10.1002/mus.22081 -
Statin Toxicity
A comprehensive, mechanistic review of statin toxicity with a focus on statin-associated muscle symptoms (SAMS), detailing the mevalonate pathway effects, mitochondrial and calcium signaling perturbations, genetic factors, clinical presentations, prevalence, potential biomarkers…
DOI: 10.1161/circresaha.118.312782